Skip to main content

VIEW LARGER COVER

The U.S. Food and Drug Administration (FDA) has responsibility for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices. In certain declared emergencies, FDA has the option to authorize use of a new product or a new use of an approved product - an authority known as Emergency Use Authorization (EUA)- if it has reason to believe that the product may be effective and that its known benefits outweigh its known risks. By contrast, in non-emergency situations, applicants must demonstrate a product's safety and effectiveness through a lengthier, more extensive process.

On October 5-6, 2021, the Committee on Science, Technology, and Law of the National Academies of Sciences, Engineering, and Medicine convened a virtual workshop on the EUA process. At the workshop, presenters and participants examined FDA's recent and historic use of EUAs, discussed lessons learned during the COVID-19 pandemic, and considered how those lessons might inform future efforts. The workshop also highlighted emergency mechanisms used by other health regulators and considered how U.S. and global regulatory partners can strengthen cooperation in responding to global health emergencies. This publication summarizes the presentation and discussion of the workshop.

Suggested Citation

National Academies of Sciences, Engineering, and Medicine. 2021. The Food and Drug Administration's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: Proceedings of a Workshop–in Brief. Washington, DC: The National Academies Press. https://doi.org/10.17226/26441.

Import this citation to:

Publication Info

13 pages | 8.5 x 11 |  DOI: https://doi.org/10.17226/26441

What is skim?

The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.

Copyright Information

The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:

  • Republish text, tables, figures, or images in print
  • Post on a secure Intranet/Extranet website
  • Use in a PowerPoint Presentation
  • Distribute via CD-ROM
  • Photocopy

Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:

Rightslink Customer Care
Tel (toll free): 877/622-5543
Tel: 978/777-9929
E-mail: customercare@copyright.com
Web: http://www.rightslink.com

To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.

To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.

Loading stats for The Food and Drug Administration's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: Proceedings of a Workshop–in Brief...